Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Griguolo

Showing results (51-60 of 131) with videos related to

Pageof 14
Sort By:
Breast (Edinburgh, Scotland)|October 27, 2017
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experienceGaia Griguolo, William Jacot, Eva Kantelhardt, et al.
NPJ Breast Cancer|November 26, 2025
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabGiorgio Bonomi, Gaia Griguolo, Tommaso Giarratano, et al.
Journal of Clinical Pathology|June 21, 2023
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort studyFederica Miglietta, Valentina Carraro, Ottavia Amato, et al.
British Journal of Cancer|June 4, 2014
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumabE Zulato, F Bergamo, A De Paoli, et al.
NPJ Breast Cancer|October 13, 2021
Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Gaia Griguolo, Michele Bottosso, et al.
NPJ Breast Cancer|February 13, 2021
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancerGaia Griguolo, Maria Vittoria Dieci, Laia Paré, et al.
NPJ Breast Cancer|November 25, 2021
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Gaia Griguolo, Michele Bottosso, et al.
Investigational New Drugs|March 21, 2017
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumorsA Stathis, D Hess, R von Moos, et al.
Breast Cancer Research and Treatment|April 5, 2017
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Pageof 14

Showing results (51-60 of 131) with videos related to

Sort By:
Pageof 14
Breast (Edinburgh, Scotland)|October 27, 2017
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experienceGaia Griguolo, William Jacot, Eva Kantelhardt, et al.
NPJ Breast Cancer|November 26, 2025
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumabGiorgio Bonomi, Gaia Griguolo, Tommaso Giarratano, et al.
Journal of Clinical Pathology|June 21, 2023
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort studyFederica Miglietta, Valentina Carraro, Ottavia Amato, et al.
British Journal of Cancer|June 4, 2014
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumabE Zulato, F Bergamo, A De Paoli, et al.
NPJ Breast Cancer|October 13, 2021
Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Gaia Griguolo, Michele Bottosso, et al.
NPJ Breast Cancer|February 13, 2021
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancerGaia Griguolo, Maria Vittoria Dieci, Laia Paré, et al.
NPJ Breast Cancer|November 25, 2021
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Gaia Griguolo, Michele Bottosso, et al.
Investigational New Drugs|March 21, 2017
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumorsA Stathis, D Hess, R von Moos, et al.
Breast Cancer Research and Treatment|April 5, 2017
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Pageof 14